Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastrointest Surg. Sep 27, 2016; 8(9): 634-642
Published online Sep 27, 2016. doi: 10.4240/wjgs.v8.i9.634
Table 1 Demographics for 103 patients undergoing total pancreatectomy with subgroup analysis
VariableOverall (n = 103)PDAC (n = 42)IPMN (n = 40)LTP (n = 24)
Age, yr170.2 (32-84.5)70.3 (33.3-84.5)71.3 (42.9-81.1)70.3 (37.3-84.5)
Body mass index125.1 (17.7-42.1)24.2 (17.7-39.8)25.8 (18.5-42.1)26.7 (17.7-36.3)
Male44 (42.7%)18 (42.9%)19 (47.5%)13 (54.2%)
Hypertension70 (68%)29 (69%)31 (77.5%)14 (58.3%)
Diabetes46 (44.7%)19 (45.2%)16 (40%)13 (54.2%)
Cardiac disease31 (30.1%)8 (19%)14 (35%)7 (29.2%)
Pulmonary disease19 (18.4%)7 (16.7%)7 (17.5%)5 (20.8%)
ASA
II24 (23.3%)11 (26.2%)9 (22.5%)2 (8.3%)
III72 (69.9%)26 (61.9%)29 (72.5%)22 (91.7%)
IV7 (6.8%)5 (11.9%)2 (5%)0
Type of resection
Standard35 (34%)17 (40.5%)10 (25%)5 (20.8%)
Pylorus preserving56 (54.4%)20 (47.6%)27 (67.5%)16 (66.7%)
Completion12 (11.6%)5 (11.9%)3 (7.5%)3 (12.5%)
Table 2 Operative variables for 103 patients undergoing total pancreatectomy with subgroup analysis
VariableOverall (n = 103)PDAC (n = 42)IPMN (n = 40)LTP (n = 24)
Operative time (min)1426 (165-930)390 (165-636)435 (240-930)534 (234-770)
Estimated blood loss (mL)1500 (50-18000)500 (50-7800)525 (50-18000)200 (50-600)
Intraoperative pRBC transfusion (unit)11 (0%-40%)2 (0%-30%)1 (0%-40%)0 (0%-2%)
Vein resection18 (17.5%)13 (40%)4 (10%)1 (4.2%)
Table 3 Postoperative outcomes and complications (90 d) for 103 patients undergoing total pancreatectomy
VariableOverall (n = 103)PDAC (n = 42)IPMN (n = 40)LTP (n = 24)
Cardiac10 (9.7%)5 (11.9%)3 (7.5%)1 (4.2%)
Pulmonary15 (14.6%)7 (16.7%)6 (15%)5 (20.8%)
Renal insufficiency8 (7.8%)3 (7.1%)6 (15%)4 (16.7%)
Hepatic insufficiency3 (2.4%)1 (2.4%)3 (7.5%)2 (8.3%)
Major glycemic event6 (5.8%)3 (7.1%)2 (5%)1 (4.2%)
Post-pancreatectomy hemorrhage5 (4.9%)0 (0.0%)4 (10%)4 (16.7%)
A2 (1.9%)02 (5%)2 (8.3%)
B1 (0.8%)001 (4.2%)
C2 (1.9%)02 (5%)1 (4.2%)
Delayed gastric emptying14 (13.6%)5 (11.9%)5 (12.5%)2 (8.3%)
A4 (4.9%)2 (4.8%)2 (5%)0
B5 (4.9%)2 (4.8%)1 (2.5%)1 (4.2%)
C5 (4.9%)1 (2.4%)2 (5%)1 (4.2%)
Wound infection11 (10.7%)5 (11.9%)2 (5%)2 (8.3%)
Intra-abdominal abscess14 (13.6%)2 (4.8%)8 (20%)4 (16.7%)
Biliary fistula2 (1.9%)01 (2.5%)0
Mesenteric/portal vein thrombosis5 (4.9%)2 (4.8%)2 (5%)1 (4.2%)
Reoperation7 (6.8%)2 (4.8%)2 (5%)2 (8.3%)
Patients intensive care stay64 (62.1%)24 (57.1%)30 (75%)10 (41.7%)
Median intensive care stay, d1 (range)2 (1-59)2 (1-12)2 (1-59)2 (1-33)
Overall morbidity66 (64.1%)27 (64.3%)25 (62.5%)10 (41.7%)
Major (III-V)33 (32%)13 (31%)13 (32.5%)5 (20.8%)
IIIa14 (13.6%)5 (11.9%)6 (15%)0
IIIb3 (2.9%)2 (4.8%)00
IVa4 (4.9%)1 (2.4%)2 (5%)2 (8.3%)
IVb5 (4.9%)2 (4.8%)1 (2.5%)2 (8.3%)
V7 (6.8%)3 (7.1%)4 (10%)1 (4.2%)
Length of stay, d1 (range)9 (3%-71%)9 (3%-71%)10 (4%-67%)8 (4%-52%)
Readmission26 (25.2%)12 (28.6%)8 (20%)3 (12.5%)
Table 4 Pathologic findings for 103 patients undergoing total pancreatectomy
VariableOverall (n = 103)LTP (n = 24)
Malignantn = 53n = 12
Pancreatic ductal adenocarcinoma42 (40.8%)5 (20.8%)
De novo23 (22.3%)3 (12.5%)
Arising from IPMN19 (18.5%)2 (8.3%)
Neuroendocrine7 (6.8%)6 (25%)
Cholangiocarcinoma with IPMN1 (0.97%)0
Ampullary adenocarcinoma with IPMN1 (0.97%)1 (4.2%)
Renal cell carcinoma1 (0.97%)0
Sarcoma1 (0.97%)0
Tumor size, cm13.5 ± 2.4 (0.5%-14%)3.2 ± 2.5 (1.3%-10%)
Margin negative (R0)41 (77.4%)11 (91.7%)
Number of lymph nodes harvested123 ± 14 (1%-61%)28 ± 11 (11%-41%)
Non malignantn = 50n = 12
IPMN40 (38.8%)11 (45.8%)
Chronic pancreatitis8 (7.8%)1 (4.2%)
Ampullary adenoma with IPMN1 (0.97%)0
Trauma1 (0.97%)0